Abstract
Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Current Pharmaceutical Design
Title:Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Volume: 19 Issue: 32
Author(s): Miriam Ojeda-Ojeda, Mora Murri, Maria Insenser and Hector F. Escobar-Morreale
Affiliation:
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Abstract: Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Export Options
About this article
Cite this article as:
Ojeda-Ojeda Miriam, Murri Mora, Insenser Maria and Escobar-Morreale F. Hector, Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS), Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320012
DOI https://dx.doi.org/10.2174/1381612811319320012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE
Current Pharmaceutical Design Lower Sodium Intake and Renal Protective Effects
Current Hypertension Reviews Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Advantages and Limitations of Transgenic Mice: The Role of the Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger in Cardiac Electrophysiology and Arrhythmia
Current Medicinal Chemistry Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets RNAi in Clinical Studies
Current Medicinal Chemistry Preface
Current Nutrition & Food Science Cardiac Cell Therapy and Bypass Surgery
Current Pharmaceutical Design Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry New Therapeutic Approaches to Arterial Calcification Via Inhibition of Transglutaminase andβ-Catenin Signalin
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension
Current Vascular Pharmacology Physiologic Responses in Anxiety
Current Psychiatry Reviews Current Problems, New Opportunities and Future Directions of Antiplatelet Therapy - Increasing Role of Novel Antiplatelet Agents in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Phytol a Natural Diterpenoid with Pharmacological Applications on Central Nervous System: A Review
Recent Patents on Biotechnology Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design